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Background. Sequence data from resistance testing offer unique opportunities to characterize the structure of
human immunodeficiency virus (HIV) infection epidemics.
Methods. We analyzed a representative set of HIV type 1 (HIV-1) subtype B pol sequences from 5700 patients
enrolled in the Swiss HIV Cohort Study. We pooled these sequences with the same number of sequences from
foreign epidemics, inferred a phylogeny, and identified Swiss transmission clusters as clades having a minimal size
of 10 and containing 80% Swiss sequences.
Results. More than one-half of Swiss patients were included within 60 transmission clusters. Most transmission
clusters were significantly dominated by specific transmission routes, which were used to identify the following
patient groups: men having sex with men (MSM) (38 transmission clusters; average cluster size, 29 patients) or
patients acquiring HIV through heterosexual contact (HETs) and injection drug users (IDUs) (12 transmission
clusters; average cluster size, 144 patients). Interestingly, there were no transmission clusters dominated by sequences
from HETs only. Although 44% of all HETs who were infected between 1983 and 1986 clustered with injection
drug users, this percentage decreased to 18% for 2003–2006 ( ), indicating a diminishing role of injectionP ! .001
drug users in transmission among HETs over time.
Conclusions. Our analysis suggests (1) the absence of a self-sustaining epidemic of HIV-1 subtype B in HETs
in Switzerland and (2) a temporally decreasing clustering of HIV infections in HETs and IDUs.
The fast evolution of human immunodeficiency virus
(HIV) enables the inference of important epidemiolog-
ic patterns from sequence data [1]. Phylogenetic meth-
ods can address questions that are very difficult to in-
vestigate otherwise, such as investigations of the early
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phase of the epidemics, for which few direct data are
available [2–5]. Furthermore, molecular methods have
been applied in identifying transmission events [6] and
characterizing large transmission chains [4, 7–11].
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Switzerland belongs to the Western European countries that
have been most strongly affected by HIV type 1 (HIV-1), as
indicated by the sustained higher prevalence of HIV-1 noted in
Switzerland, compared with its neighboring countries of Ger-
many, France, and Italy [12]. The structure of the Swiss epidemic
is typical of such epidemics seen in Western Europe. The pre-
dominant transmission routes were used to identify the following
patient groups: injection drug users (IDUs), men who have sex
with men (MSM), and individuals acquiring HIV through het-
erosexual intercourse (HETs). Although HIV-1 transmission
preferentially occurs among individuals with the same risk factor,
interactions between transmission groups (eg, prostitution
among IDUs or bisexuality) might play an important role as well.
An additional and increasingly more important layer of com-
plexity in the study of disease dynamics emerges from infections
acquired abroad, either through travel to foreign countries or
immigration [13]; this complexity is also evidenced by the in-
creasing proportion of non-B subtypes noted among recently
infected patients over the past years [14]. Disentangling these
factors is crucial for understanding the driving forces of the
epidemic and, thereby, for developing targeted prevention of HIV
transmission.
Genotypic drug resistance testing has been routinely per-
formed in Switzerland since 2000. This practice has led to a
wealth of sequence data. Moreover, the data have been con-
siderably complemented by retrospective sequencing of stored
blood samples. The sampling times for these retrospectively
sequenced samples go back to 1995, and the years of enrollment
of the patients covered reach back to 1984. Sequence data have
been linked to the Swiss HIV Cohort Study (SHCS), which
collects clinical data from a representative fraction (49%) of
the HIV-infected individuals living in Switzerland [15]. The
unique features of the SHCS are the large proportion of women
and the good representation of all transmission groups (IDUs,
MSM, and HETs). The SHCS drug resistance database contains
sequence data for 56% of the 15,000 patients who ever enrolled
in the SHCS and thus provides a representative picture of the
HIV epidemic in Switzerland.
Using phylogenetic clustering methods, we sought to identify
and characterize chains of transmission of HIV-1 subtype B
within Switzerland. In particular, we set out to analyze mixing
patterns between transmission groups and the associated tem-
poral trends.
MATERIALS AND METHODS
Sequences and patients. The SHCS is a nationwide, prospec-
tive, clinic-based cohort study with continuous enrollment and
semiannual study visits [16]. The SHCS has been approved by
the ethics committees of all participating institutions, and writ-
ten, informed consent has been obtained from participants.
The SHCS drug resistance database contains all HIV resistance
tests performed by the 4 laboratories engaged in HIV resistance
testing in Switzerland and stored in a central database devel-
oped and hosted by SmartGene (Integrated Database Network
System version 3.5.0; SmartGene) [17]. Resistance data stem
from routine clinical testing (60% of tests) and from tests ret-
rospectively performed using frozen repository plasma samples
(40% of tests). Retrospective sequencing was systematically per-
formed using the oldest available plasma sample from each
patient. All laboratories are performing population-based se-
quencing of the full protease gene and, at a minimum, codons
28–225 of the reverse-transcriptase gene, by use of commercial
assays (Viroseq, version 1 [PE Biosystems]; Virsoseq, version 2
[Abbott]; and vircoTYPE HIV-1 Assay [Virco Lab]) and in-
house methods [18].
The SHCS drug resistance database contains 11,841 se-
quences from 8572 patients with at least partial protease and
reverse-transcriptase sequences available. The sequence lengths
range from 900 to 1497 bp. The predominant subtype of the
Swiss HIV-1 epidemic is subtype B [14, 19], and therefore we
restricted our sample to subtype B viruses ( se-np 9157
quences). Only the oldest sequence available from each patient
was included in the data set, leaving 5700 sequences. To identify
clusters of Swiss sequences, we added the same number of
randomly selected non-Swiss subtype B sequences from the Los
Alamos Sequence database [20]. These sequences stem mainly
from the United States (proportion, 34%), Italy (16%), Spain
(5%), Canada (5%), Brazil (5%), Great Britain (4%), Argentina
(4%), Germany (4%), France (3%), Hungary (3%), and 47
other countries (18%). To avoid distortion of our analysis re-
sulting from convergent evolution driven by antiretroviral ther-
apy, we removed all major amino acid positions that are as-
sociated with antiretroviral drug resistance, in accordance with
the International AIDS Society (IAS)–USA guidelines [21] (po-
sitions 30, 32, 33, 46–48, 50, 54, 76, 82, 84, 88, and 90 in the
protease and 41, 62, 65, 67, 69, 70, 74, 75, 77, 100, 103, 106,
108, 115, 116, 151, 181, 184, 188, 190, 210, 215, 219, 225, and
236 in the reverse transcriptase).
The sequences analyzed in the present study constitute a data
set that is very representative of an entire country. In recent
study years, the sampling density has reached almost 80% of
all patients with an AIDS diagnosis. Such data would, in prin-
ciple, allow for the reconstruction of entire transmission net-
works and could thereby endanger the privacy of the patients.
This is especially problematic because HIV-1 sequences fre-
quently have been used in court cases. From a scientific point
of view, the consequences of open and uncontrolled access to
such densely sampled sequences could jeopardize the future
publication (and, thus, the investigation) of similarly complete
data sets and could thereby be counterproductive even from
an “open-access” perspective. For these reasons, we decided to
make only a random subset of 10% of the sequences accessible
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via GenBank (accession numbers, GU344102–GU344671). We
would, however, like to point out that all data in the SHCS
can be used for well-defined projects that are in accordance
with the guidelines of the SHCS, if a corresponding project
proposal is approved by the SHCS scientific board.
Demographic data (on transmission groups and geographical
origin in Switzerland) and administrative data (on the year that
sampling was performed, the year of the enrollment of the
patient in the cohort, and the year that the first positive HIV
test result occurred) were obtained from the SHCS database.
The year of infection was estimated as described elsewhere [22].
In brief, dates were obtained from a back-calculation model
that incorporates the dates at which the first positive or last
negative HIV test results and CD4 cell counts were obtained
as predictor variables. These dates could be calculated for 4563
(80%) of 5700 patients. Patients were categorized into the fol-
lowing groups on the basis of transmission routes: IDUs (1773
sequences), MSMs (2547 sequences), and HETs (1390 se-
quences). Other transmission modes (eg, perinatal and trans-
fusion risks) were not considered. Years of sampling ranged
from 1989 to 2007 (median sampling year [interquartile range
{IQR}], 2000 [1997 to 2003]), whereas the year of enrollment
into the SHCS ranged from 1984 to 2008 (median year of
enrollment [IQR], 1997 [1992 to 2001]). The estimated year
of infection ranged from 1981 to 2007 (median year of infec-
tion [IQR], 1992 [1988 to 1997]).
Phylogenetic methods. We inferred a maximum-likelihood
tree, using the GTRCAT [23] method (which is a computational
approximation of the GTR model with G-distributed rate het-
erogeneity) implemented in RAxML [24]. We verified the re-
sults inferred from this tree on several trees derived on the basis
of alternative methods (see Discussion). Transmission clusters
were inferred from this tree in a way similar to that described
by Hue et al [4]: “Swiss transmission clusters” were defined as
clades that consisted of80% sequences from Switzerland and
that contained 10 sequences. The minimal size was chosen
to exclude clusters that would also occur if Swiss and foreign
patients were randomly distributed on the phylogeny: with in-
creasing cluster size, clusters with 80% sequences from Swit-
zerland become less likely by chance; for a size of 10, the prob-
ability of finding such a cluster by chance is 0.05 (under a
binomial model).
RESULTS
A maximum-likelihood tree was inferred from the 11,400 se-
quences of our data set (5700 sequences from the SHCS plus
the same number of sequences from the Los Alamos HIV da-
tabase). In this tree, we identify Swiss transmission chains (or
subepidemics) as clades (or subtrees) that have a minimal size
of 10 and for which 80% of the sequences stem from Swit-
zerland (see Materials and Methods and [4]). The intuition
behind this definition is that if a group of Swiss patients stems
from a Swiss transmission chain, then the sequences from these
patients should be more closely related to each other than to
sequences from foreign epidemics. Hence, these sequences
should form a clade in a phylogeny, even if this phylogeny
contains sequences from foreign epidemics. According to this
reasoning, Swiss transmission chains can be identified as clades
of Swiss sequences in a phylogeny that contains sequences from
both Switzerland and abroad. There are, however, at least 2
reasons why subepidemics in Switzerland do not have to lead
to clades that are composed uniquely of Swiss sequences. First,
individual patients can either emigrate or infect patients outside
of Switzerland. These non-Swiss patients will belong to the same
clades as the Swiss patients, even if the latter patients form a
largely domestic transmission chain. Second, it is well known
that HIV trees are subject to a large topological uncertainty
(see Discussion); therefore, occasional misattributions of in-
dividual patients to wrong clades are likely to occur. Intuitively,
the inference of transmission chains from clades should there-
fore be robust against these 2 processes. One possibility to
achieve this is to identify Swiss transmission chains not as clades
that are composed uniquely of Swiss sequences but, rather, as
clades for which the fraction of Swiss sequences exceeds some
(large) threshold. The concrete choice of such a threshold is,
to some extent, ad hoc (with the restriction that it should
considerably exceed the average fraction of Swiss sequences in
the entire phylogeny). For the present study, we have chosen
a threshold of 80%, but we have found qualitatively identical
results for different values of this threshold (results not shown).
In summary, we identify transmission chains as clades domi-
nated by Swiss sequences. In the remainder of the text, we will
refer to these as (Swiss) transmission clusters.
Sequences cluster according to transmission group. Figure
1 highlights the distribution of the Swiss sequences in the
phylogeny. It indicates the presence of 2 types of transmission
clusters: the “IDU/HET transmission clusters,” which mainly
consist of patients who have acquired HIV through hetero-
sexual contact or injection drug use, and the “MSM trans-
mission clusters,” which mainly consist of patients for whom
homosexual intercourse between men is the primary route of
transmission.
Overall, we found 60 Swiss transmission clusters containing
3120 (55%) of all SHCS sequences (Table 1 characterizes the
20 largest clusters, with a minimum cluster size of 30 individ-
uals). Of these 60 transmission clusters, 50 contain a significant
(according to a binomial test) excess of either MSM (38 trans-
mission clusters; 1100 patients) or IDUs and HETs (12 trans-
mission clusters; 1725 patients). Thus, IDUs and HETs segre-
gated into fewer but larger transmission clusters (mean size,
144 individuals; 82% of patients in IDU/HET transmission
clusters belonged to the 3 largest transmission clusters), com-
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Figure 1. A, Maximum-likelihood tree of the entire sequence data set (30 subtype C sequences from the Swiss HIV Cohort Study [SHCS] data set were
used as an outgroup). Colors denote the origin and risk group: black denotes non-Swiss origin, cyan denotes Swiss origin and men who have sex with
men (MSM), red denotes Swiss origin and patients acquiring human immunodeficiency virus via heterosexual contact (HET), blue denotes Swiss origin
and injection drug user (IDU). B, Same tree as shown in panel A but in which Swiss transmission clusters are denoted by triangles. Red denotes significant
dominance of MSMs, blue denotes significant dominance of IDUs and HETs, and dark gray denotes no significant dominance by either transmission group.
pared with MSMs (mean size, 29 individuals; 36% of patients
in the 3 largest transmission clusters), suggesting more-inde-
pendent subepidemics and smaller transmission chains for the
MSM epidemic.
The transmission clusters differ considerably with regard to
the dates of infection obtained from the back-calculation
model. (Figure 2 shows the ranges of dates of infection for the
20 largest clusters.) Transmission clusters were classified as old
or young, depending on whether the oldest infection occurred
before or after 1990. We found that most patients (96%) in
Swiss transmission clusters belong to 55 “old” transmission
clusters. However, the phylogeny does also contain 5 “young”
transmission clusters, which include 4% of patients that belong
to Swiss transmission clusters.
Interactions between transmission groups. Table 2 shows
how the transmission groups are distributed over the different
cluster types. Overall, 72% of the IDU sequences but only 42%
of the MSM sequences belong to Swiss transmission clusters.
Thus, MSM sequences clustered particularly poorly, indicating
an important role of infections acquired abroad, whereas do-
mestic infection events seem to dominate HIV-1 epidemics
among IDUs. Furthermore, Table 2 indicates considerable mix-
ing between the HET and MSM groups: 11% of the HET se-
quences stem from MSM transmission clusters. By contrast only
2% of IDU sequences were associated with MSM transmission
clusters. These findings were further corroborated and extended
by results from a multinomial logistic regression model, to
investigate associations of demographic factors with IDU/HET
transmission clusters or MSM transmission clusters, using un-
clustered sequences as a reference (Table 3). Clustering of se-
quences in IDU/HET transmission clusters was associated with
a smaller probability of the origin of the patients being outside
of Western Europe and a higher probability of patients being
female, having injection drug use as a presumed mode of HIV
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Figure 2. Median (yellow dots) value and range (bars) of the years of
infection for the patients in the 20 largest transmission clusters shown in
Table 1. The height of the bars is proportional to the number of patients
in the corresponding transmission clusters. Red denotes significant domi-
nance of men who have sex with men (MSM), blue denotes significant
dominance of injection drug users (IDUs) and patients acquiring human
immunodeficiency virus via heterosexual contact (HETs), and dark gray de-
notes no significant dominance by either transmission group.
Table 2. Distribution of the Patients from the Different Transmis-
sion Groups over the Different Cluster Types
Transmission
group
MSM
cluster
IDU/HET
cluster
Ambiguous
cluster
No transmission
cluster
MSM 903 (36) 86 (3) 83 (3) 1469 (58)
HET 159 (11) 525 (38) 87 (6) 617 (44)
IDU 37 (2) 1113 (63) 125 (7) 490 (28)
NOTE. Data are the no. (%) of patients. HET, patients acquiring HIV via het-
erosexual transmission; IDU, injecting drug users; MSM, men having sex with
men.
acquisition, and having been infected with HIV before 1996.
In contrast, factors associated with MSM transmission clusters
were being male, acquisition of HIV through homosexual con-
tact between men, and enrollment into the SHCS in a study
center from the German-speaking part of Switzerland.
A particularly interesting aspect of interactions between
transmission groups is the source of infection of patients in
the HET group. If transmission among HETs would be able
to sustain an epidemic in Switzerland independently of other
risk groups, we would expect to find large clusters that are
dominated by HET sequences (in particular, given that IDUs
are, overall, such a small population, compared with HETs).
However, the phylogenetic tree contains no such clusters. The
largest cluster, with at least 80% HETs, is only 9 sequences
large; by contrast, the corresponding clusters for MSMs and
IDUs have sizes of 239 sequences and 42 sequences, respec-
tively. (See Figure A1 in Appendix A, which appears only in
the electronic version of the Journal, for the size distribution
of transmission clusters that are dominated by a particular
transmission group.) Thus, although HETs are well repre-
sented in our database (see Figure A2 in Appendix A, which
appears only in the electronic version of the Journal), the
sequence data show no evidence for large HET-dominated
transmission chains in Switzerland. To resolve the origin of
the HET sequences, we subdivided them into 3 categories
according to their clustering with sequences of other trans-
mission groups (Table 2): (1) those that cluster with IDU
sequences (ie, that belong to the IDU/HET transmission clus-
ters), (2) those that cluster with MSM sequences, and (3)
those that do not belong to Swiss transmission clusters. IDU-
and MSM-associated HET sequences can be interpreted as
offshoots of the epidemics in IDUs and MSM, respectively,
whereas HET sequences that belong to no larger transmission
cluster most plausibly stem from non-Swiss epidemics.
Temporal trends in the interaction between transmission
groups. Interestingly, infection dates indicate a shift between
the 2 major sources of the HET epidemics (Figure 3). In the
early phase of the epidemics, a slightly larger amount of in-
fections (44%) stemmed from the Swiss IDU epidemic than
from foreign epidemics (38%). Subsequently, however, the im-
portance of the IDU epidemic decreased considerably such that
the association with IDU has almost become negligible, com-
pared with the effect of foreign epidemics (18% versus 71% of
sequences belong to the respective categories for 2003–2006).
A test for trend shows that the decrease in the effect of the
IDU epidemic on the HET epidemic is statistically significant
( ). Moreover, Figure 3 shows that new HET infectionsP ! .001
associated with IDUs seem to have decreased in absolute num-
bers over time, although we cannot fully exclude an effect of
delays in diagnosis of HIV infection and enrollment into the
SHCS for later time periods. In contrast to HETs, no significant
temporal trend was found regarding the origin of MSMs and
IDUs (results not shown).
The influence of geographical structure. Concerning the
geographical origin of the HIV-1–infected individuals, the
strongest segregation can be observed between German- and
French-speaking regions. Overall, 74% and 26% of the se-
quences stem from German- and French-speaking parts of
Switzerland, respectively. Patients from German-speaking re-
gions are significantly ( under a binomial null-model)P ! .05
overrepresented in 14 transmission clusters containing 604
patients, whereas patients from French-speaking regions are
overrepresented in 10 transmission clusters containing 399 pa-
tients. Thus, the phylogeny indicates that geographical struc-
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Table 3. Associations of Demographic Factors with Cluster Type, as Inferred from a Multinomial Logistic Regression Model
Factor
No
cluster
(n p 2577)
IDU/HET
cluster
(n p 1725)
MSM
cluster
(n p 1100)
AMBIG
cluster
(n p 295)
IDU/HET
RRR (95% CI)a
MSM
RRR (95% CI)a
AMBIG
RRR (95% CI)a
ART status at sampling
Naive 1212
(47.0)
841
(48.8)
553
(50.3)
135
(45.8)
Reference Reference Reference
Experienced 1365
(53.0)
884
(51.2)
547
(49.7)
160
(54.2)
0
.76 (.65–0.89)
0
.94 (0.80–1.11)
1
.07 (0.82–1.40)
Years of infection
1981–1986 354
(13.7)
432
(25.0)
95
(8.6)
53
(18.0)
1
.84 (1.39–2.43)
0
.77 (0.57–1.03)
0
.91 (0.58–1.43)
1987–1991 559
(21.7)
509
(29.5)
191
(17.4)
63
(21.4)
1
.76 (1.37–2.27)
0
.95 (0.75–1.21)
0
.81 (0.54–1.23)
1992–1995 494
(19.2)
320
(18.6)
239
(21.7)
62
(21.0)
1
.55 (1.19–2.00])
1
.17 (0.93–1.48)
1
.01 (0.68–1.51)
1996–2000 483
(18.7)
276
(16.0)
242
(22.0)
53
(18.0)
1
.46 (1.13–1.88)
1
.20 (0.96–1.48)
0
.95 (0.64–1.41)
2001–2007 687
(26.7)
188
(10.9)
333
(30.3)
64
(21.7)
Reference Reference Reference
Sampling done during primary HIV infection
No 2099
(81.5)
1452
(84.2)
907
(82.5)
244
(82.7)
Reference Reference Reference
Yes 478
(18.5)
273
(15.8)
193
(17.5)
51
(17.3)
1
.18 (0.96–1.45)
0
.84 (0.69–1.02)
1
.07 (0.77–1.50)
Location of enrollment into SHCS
French-speaking area 780
(30.3)
403
(23.4)
219
(19.9)
61
(20.7)
0
.83 (0.70–0.98)
0
.59 (0.49–0.70)
0
.67 (0.49–0.90)
German-speaking area 1797
(69.7)
1322
(76.6)
881
(80.1)
234
(79.3)
Reference Reference Reference
Region of origin
Outside Western Europe 604
(23.4)
232
(13.4)
180
(16.4)
47
(15.9)
0
.58 (0.41–0.81)
0
.51 (0.42–0.62)
0
.70 (0.58–0.85)
Western Europe 1973
(76.6)
1493
(86.6)
920
(83.6)
248
(84.1)
Reference Reference Reference
Presumed mode of HIV acquisition
HET 617
(23.9)
526
(30.5)
159
(14.5)
87
(29.5)
Reference Reference Reference
IDU 490
(19.0)
1113
(64.5)
38
(3.5)
125
(42.4)
2
.22 (1.87–2.65)
0
.27 (0.18–0.39)
1
.63 (1.18–2.25)
MSM 1470
(57.0)
86
(5.0)
903
(82.1)
83
(28.1)
0
.07 (0.05–.09)
1
.65 (1.31–2.08)
0
.33 (0.23–0.47)
Sex
Female 476
(18.5)
707
(41.0)
56
(5.1)
77
(26.1)
1
.10 (0.93–1.29)
0
.43 (0.31–0.60)
0
.80 (0.59–1.10)
Male 2101
(81.5)
1018
(59.0)
1044
(94.9)
218
(73.9)
Reference Reference Reference
NOTE. Data are the no. (%) of patients, unless otherwise indicated. AMBIG, ambiguous cluster; ART, antiretroviral therapy; CI, confidence interval; HET, patients
acquiring HIV via heterosexual transmission; HIV, human immunodeficiency virus; IDU, injecting drug users; MSM, men having sex with men. NA, not applicable;
RRR, relative risk ratio; SHCS, Swiss HIV Cohort Study.
a 95% confidence intervals not including 1 denote statistically significant associations.
ture, even within a small country such as Switzerland, has a
considerable influence on the spread of HIV.
DISCUSSION
Using 5700 subtype B pol sequences from a nationwide and
representative database of HIV-1 nucleotide sequences, we
characterized the epidemics of HIV-1 in Switzerland since the
early 1980s. The broadest pattern observed was the strong sep-
aration between the transmission clusters dominated by MSMs
and those dominated by IDUs and HETs. Separation of IDUs
from other transmission groups (mainly MSMs and hemo-
philiacs) has previously been found in a number of smaller
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Figure 3. Distribution of sequences from individuals who acquired human
immunodeficiency virus via heterosexual contact (HET) over different trans-
mission cluster types as a function of time. A, The proportion of HET that
belong to a particular transmission cluster type (see key). B, The corre-
sponding absolute numbers. IDU, injection drug users; MSM, men who have
sex with men,
studies [9, 10, 25, 26], whereas an association between IDUs
and HETs has only been documented for a fairly small study
based on patients from Edinburgh [9]. On top of this broad
separation, we have found a weaker but still substantial ex-
change between HETs and MSMs, which has not been found
in previous molecular epidemiology studies. The transmission
clusters also showed a clear signature of geographical separation
(in contrast to [25]). However, this signature reached a sig-
nificant level only in a few transmission clusters, and, overall,
geography seemed to have a considerably weaker effect than
transmission mode, such as injection drug use or sex between
men. In other words, transmission events occur preferentially
within the same transmission groups and within the same re-
gion, but HIV-1 infections cross geographical regions much
more frequently than they cross transmission groups.
In Switzerland, the number of new HIV infections strong-
ly decreased in the late nineties, but increases in incident HIV-
1 infections have been noted again in recent years, especially
among MSM [27]. Interestingly, we found several transmission
clusters that emerged only very recently, with the majority (4
of 5) of those dominated by sequences from MSMs. This find-
ing suggests that the recent increase in the epidemics might, at
least in part, be due to recent transmission clusters and not to
the growth of the older, established transmission clusters. This
finding is in line with recent observations that recently infected
patients are an important driver for the HIV epidemic [11, 28–
30]. Thus, prevention measures have to target specifically these
newer and also younger transmission networks, to be more
successful in the future.
Caveats. As in all (molecular) epidemiology studies, sam-
pling could potentially distort our results. For example, it is,
in principle, conceivable that the absence of large HET-dom-
inated transmission chains is just an artifact of sampling. This
could be the case if our sample systematically omits entire sub-
populations of HETs among which large transmission chains have
occurred. We think, however, that such a scenario is unlikely for
a reportable infection, which (even though after a delay) leads
to very severe symptoms. A related issue is that, even under the
assumption of a homogenous sampling, we underestimate the
length of transmission chains because our sample is incomplete.
However, because our sampling density is high for all transmis-
sion groups (see Figure A2), this effect will be moderate. More-
over, because the sampling density is comparable for the 3 trans-
mission groups (see Figure A2 in Appendix A, which appears
only in the electronic version of the Journal), the incompleteness
of the sampling does not affect the relative contribution of the
different transmission routes. Concerning temporal aspects of
the sampling, it should first be noted that the time of infection
is only a rough estimate obtained using a back-calculation meth-
od (see Materials and Methods). Second, although our data
set has an exceptional temporal depth (because the sequences
stem not only from drug resistance tests but also from the se-
quencing of stored plasma samples), the sampling intensity is
not homogenous over time and might therefore distort temporal
trends of the absolute numbers of patients (such as the pattern
shown Figure 3B). However, interpretations of relative numbers
of patients (such as the key result that the fraction of HETs
clustering with IDUs decreases over time) obviously are not af-
fected by these problems. In summary, we think that although
sampling might affect the quantitative details of our results, the
large qualitative patterns are robust against it. This is not least
because of the exceptional completeness and temporal depth of
our sample, which is as representative as it gets for epidemics in
an entire county over a time span of 2 decades.
We furthermore assessed the robustness of our results both
with respect to the method of inferring the phylogenetic tree
and with respect to the nucleotide positions considered (see
Appendix B, which is available only in the electronic version
of the Journal, for supplementary material on tests of robust-
ness). These analyses show that the detailed composition of the
transmission clusters is not robust; however, on the other hand,
they also underline the robustness of the broad qualitative pat-
terns described in this article. Finally, it should be noted that
our conclusions are restricted to the HIV-1 subtype B epidemics
in Switzerland. This especially concerns our finding that large
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transmission chains dominated by HETs are absent in Swit-
zerland. With an increasing number of non–subtype B infec-
tions (which occur mainly in migrants), there could be, for
instance, a burgeoning epidemic of heterosexually transmitt-
ed non–B subtype HIV-1 within the migrant community in
Switzerland.
Conclusion. Although the association between IDUs and
HETs is, overall, a prominent feature in the Swiss HIV epi-
demics, our data also show that it has become considerably
weaker, especially in comparison to migration. This shift from
injection drug use–associated infections to infections from
foreign epidemics probably reflects 2 complementary devel-
opments. On the one hand, the importance of migration has
increased. On the other hand, the epidemics among IDUs have
strongly decreased because of effective prevention (eg, needle
exchange programs [31, 32]), and, as a secondary effect, fewer
HETs have been infected by IDUs. Our analysis indicates that
the second factor was most likely responsible for the major part
of the shift and thus supports the view that heterosexuals in-
directly profited from the prevention among the IDU com-
munity. Thus, the decreasing effect of IDUs on the HET epi-
demic indicates that prevention measures targeted at IDUs,
such as needle exchange programs, can result in substantial
alleviations for other transmission groups as well.
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